MINUTES: Methylation, mIcrobiome, NUtritional sTatus, and dEvelopment of Stunted Children

Sponsor
SEAMEO Regional Centre for Food and Nutrition (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05779904
Collaborator
London School of Hygiene and Tropical Medicine (Other), University of Aberdeen (Other)
300
11

Study Details

Study Description

Brief Summary

The investigators will conduct a case-control study among under-two children in Lombok Timur, West Nusa Tenggara, Indonesia. The power required to detect changes in epigenetic markers may not be sufficient in the cohort study. Therefore, specific case-control design of stunted vs non-stunted children will provide the required power to detect potential epigenetic markers which will be further investigated through targeted sequencing of the cohort study. A total of 150 stunted children will be recruited and then it will be matched with 150 non-stunted children with the same sex. The assessments for these study subjects will include: 1) The genetic and epigenetic profile of the children, gut microbiota and nutritional status (Physical component), 2) Food security, Water, Sanitation and Hygiene (WASH) and Infant and Young Child Feeding (IYCF) practices (Home-Food component), 3) Children's psychosocial care and cognitive outcome (Cognition component).

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    This study is part of Action Against Stunting Hub, an observational cohort study aimed to build evidence based on exploring the drivers of stunting from different perspectives and understand the impact of different interventions across three countries: India, Indonesia and Senegal. This study is intended to give the overview of stunting and its determinants among under-two children growing up during period of Covid-19 pandemic in Lombok Timur, Nusa Tenggara Barat, Indonesia. Because, the power required to detect changes in epigenetic markers may not be sufficient in the cohort study, this specific case-control design of stunted vs non-stunted children will also provide the required power to detect potential epigenetic markers which will be further investigated through targeted sequencing of the cohort study. The results of this initial study are projected to support further study, especially the observational cohort study, in determining the best suited indicators to prove the interaction and/or causal mechanisms of stunting.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    300 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Cross-Sectional
    Official Title:
    DNA Methylation, Microbiome Profile, Nutritional Status, and Developmental Outcomes of Stunted and Non-stunted Children Growing up During Covid-19 Pandemic: a Case-control Study
    Anticipated Study Start Date :
    Mar 31, 2023
    Anticipated Primary Completion Date :
    Dec 31, 2023
    Anticipated Study Completion Date :
    Mar 1, 2024

    Arms and Interventions

    Arm Intervention/Treatment
    Stunted (Case)

    In the case group, stunted children (<-2SD) (n=150) will be recruited.

    Non-stunted (Control)

    In the control group, non-stunted children (>-1SD) (n=150) will be recruited.

    Outcome Measures

    Primary Outcome Measures

    1. Epigenetics signature related to stunting [at enrollment]

      Analysis of epigenetic states (DNA methylation) will be carried out using the Illumina Infinium Methylation EPIC V.2.0 BeadChip, augmented by sequencing methodologies to provide both genome wide coverage and high-definition analysis. Epigenetic state controls gene expression and overall genome regulation at scale and the study will focus on candidate epigenetic states implicated in stunting and its corollaries alongside epigenome wide association.

    Secondary Outcome Measures

    1. Child congnition outcomes (by psychologists) [at enrollment]

      Cognitive development will be assessed using the full Bayley Scales of Infant and Toddler Development (BSID-4) by trained psychologists. BSID-4 consists of: Cognitive Scale (COG); Language Scale (LANG), and Motoric Scale (MOT). The range of Standard Score (SS) of each scale is 40-160 in which higher score means better.

    2. Child cognition outcomes (care giver reported) [at enrollment]

      Cognitive development will be assessed using the care giver reported tool, i.e., INTERGROWTH-21st Neurodevelopment assessment INTER-NDA by trained enumerators. INTER-NDA consists of: Cognitive; Fine motor; Gross motor; Language; Positive behavior; Negative behavior. The range of score on each scale is 0 - 100 in which higher score means better.

    3. Gut microbiome [at enrollment]

      Faecal microbiome would be analyzed using 16S RNA sequencing of the V4 region on the Illumina MiSeq and BSAS.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Months to 23 Months
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • aged 18.0 - 23.9 months

    • without serious illnesses

    • the mother delivered the children between 18-40 years of age

    • has Sasak ethnicity, (5) recumbent length <-2SD (for stunted group) and >-1SD (for non- stunted group) from the WHO Child Growth Standards median for their age and sex at the recruitment.

    Exclusion Criteria:
    • twin birth

    • congenital malformation

    • consanguinity

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • SEAMEO Regional Centre for Food and Nutrition
    • London School of Hygiene and Tropical Medicine
    • University of Aberdeen

    Investigators

    • Principal Investigator: Umi Fahmida, Dr., SEAMEO RECFON

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Dr.Umi Fahmida, Senior Researcher, SEAMEO Regional Centre for Food and Nutrition
    ClinicalTrials.gov Identifier:
    NCT05779904
    Other Study ID Numbers:
    • AASH Early Year Study
    First Posted:
    Mar 22, 2023
    Last Update Posted:
    Mar 22, 2023
    Last Verified:
    Mar 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Dr.Umi Fahmida, Senior Researcher, SEAMEO Regional Centre for Food and Nutrition
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 22, 2023